CEO Doubles Down. $864K Buy Near Support.
Chairperson Martine Rothblatt just dropped $864K on UTHR shares at $575.96, marking her latest purchase in a biotech name she knows inside out. The buy came right above technical support at $561, with momentum building and short-to-long timeframes all aligned bullish despite the broader trend still negative. Healthcare's been choppy with regulatory noise, but this CEO has skin in the game at levels that matter. Worth noting the mixed track record here though — previous insider buys on UTHR have been hit-or-miss over 90 days.
The Filing
| Ticker | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider | Martine Rothblatt, Chairperson & CEO |
| Buy amount | $863,947 |
| Filing date | May 27, 2026 |
| Conviction | Interesting · 61/100 |
| Setup type | Accumulation |
Ultimate members received this analysis in real time.